Added to YB: 2026-09-14
Pitch date: 2026-09-11
IOVA [neutral]
Iovance Biotherapeutics, Inc.
Author Info
No bio for this author
Company Info
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
Market Cap
$3.8B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-14.55
P/E
-11.94
EV/Sales
10.98
Sector
Biotechnology
Category
growth
Biotech Conference Coverage Day 3 Session 4 - Iovance Biotherapeutics, Inc.
IOVA (quick overview): Iovance offers commercial validation through Amtagvi, with Q2 sales rising to $91 million from $60 million in Q1 and gross margin expanding to 56% from 41%. At roughly $8.70, meaningful upside depends on lifileucel succeeding in lung cancer; the key Q4 2026 data must show durable, sufficiently differentiated responses and acceptable safety from the modified lymphodepletion regimen, while treatment complexity and manufacturing execution remain risks.
Read full article (2 min)